Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials

Overview of attention for article published in Frontiers in Public Health, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,282 followers.

RT @FrontPubHealth: New Research: Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-an…

17 Aug 2022

Reply Repost Favourite

New Research: Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials: Background Sacubitril-valsartan was recommended for heart failure… https://t.co/aIac301LjX #Publ

17 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.